Introducing the use of sterile maggots into a primary care trust: overcoming barriers.
Larval therapy has been available to patients in hospital where there has been a clinical need. Not all primary care trusts realize the clinical and cost effectiveness of this treatment, or if they do, are prepared to recognise funding to allow patients to receive this treatment in the privacy of their own home. Funding can be an issue as can instigating changes in practice, particularly when there are clinicians and managers who have an aversion to the therapy.